MA28142A1 - Medicament contenant un acide (2r)-2-propyloctanoique comme principe actif - Google Patents

Medicament contenant un acide (2r)-2-propyloctanoique comme principe actif

Info

Publication number
MA28142A1
MA28142A1 MA28991A MA28991A MA28142A1 MA 28142 A1 MA28142 A1 MA 28142A1 MA 28991 A MA28991 A MA 28991A MA 28991 A MA28991 A MA 28991A MA 28142 A1 MA28142 A1 MA 28142A1
Authority
MA
Morocco
Prior art keywords
propyloctanoic acid
active ingredient
drug
drug containing
present
Prior art date
Application number
MA28991A
Other languages
English (en)
Inventor
Masao Sudoh
Seiichi Tanikawa
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of MA28142A1 publication Critical patent/MA28142A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Details Of Rigid Or Semi-Rigid Containers (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention porte sur un médicament qui est utile contre les maladies neurodégénératives, qui comprend 1 à 5 équivalents environ de l'ion de métal basique basé sur 1 équivalent de l'acide (2R)-2-propyloctanoïque ou son sel, qui est pourvu d'un sel de métal d'un acide faible ou un hydroxyde de métal, et comprend facultativement un additif de plus. Le médicament de la présente invention est un médicament qui possède un pH convenable pour l'administration par voie intraveineuse. Il est résistant au changement de pH et n'est pas pulvérisé quand il est dissout dans une infusion ou une injection, et les propriétés similaires peuvent être préparées par l'emploi d'un liquide de dissolution et/ou d'un liquide de dilution.
MA28991A 2003-10-03 2006-05-02 Medicament contenant un acide (2r)-2-propyloctanoique comme principe actif MA28142A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003345124 2003-10-03

Publications (1)

Publication Number Publication Date
MA28142A1 true MA28142A1 (fr) 2006-09-01

Family

ID=34419441

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28991A MA28142A1 (fr) 2003-10-03 2006-05-02 Medicament contenant un acide (2r)-2-propyloctanoique comme principe actif

Country Status (21)

Country Link
US (1) US8053599B2 (fr)
EP (1) EP1669065B1 (fr)
JP (1) JP4715515B2 (fr)
KR (1) KR101144553B1 (fr)
CN (1) CN1889942B (fr)
AU (1) AU2004277826B2 (fr)
BR (1) BRPI0415001A (fr)
CA (1) CA2540670A1 (fr)
EC (1) ECSP066477A (fr)
ES (1) ES2390055T3 (fr)
IL (1) IL174655A0 (fr)
IS (1) IS8430A (fr)
MA (1) MA28142A1 (fr)
MX (1) MXPA06003533A (fr)
NO (1) NO20061460L (fr)
NZ (1) NZ546231A (fr)
RU (1) RU2388467C2 (fr)
SG (1) SG146687A1 (fr)
TW (1) TW200519080A (fr)
WO (1) WO2005032536A1 (fr)
ZA (1) ZA200602690B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200613009A (en) * 2004-06-11 2006-05-01 Ono Pharmaceutical Co Capsule having chewing stability
MY147790A (en) * 2005-04-28 2013-01-31 Takeda Pharmaceutical Stable emulsion composition
JP5541845B2 (ja) * 2008-03-28 2014-07-09 Ｊｃｒファーマ株式会社 アトピー性皮膚炎治療剤
AU2009312235B2 (en) * 2008-11-04 2014-01-16 Aska Pharmaceutical Co., Ltd. Aqueous composition containing follicle-stimulating hormone
CN102159229A (zh) 2008-11-20 2011-08-17 帝国制药美国公司 吡唑啉酮衍生物制剂
JP5759804B2 (ja) * 2011-06-27 2015-08-05 富士フイルム株式会社 容器詰製剤
JP2018052861A (ja) * 2016-09-29 2018-04-05 ノーベルファーマ株式会社 ホスフェニトインナトリウム注射剤
WO2020128928A1 (fr) * 2018-12-19 2020-06-25 Jafari Javid Mihan Formulation pour le traitement de troubles neurodégénératifs ainsi que de démyélinisation et neuropathiques et sa méthode de préparation
CN110441421B (zh) * 2019-08-02 2022-09-09 聊城高新生物技术有限公司 一种高效液相色谱法测定恩他卡朋片溶出度的方法
CN112180095B (zh) * 2020-06-04 2023-10-13 三诺生物传感股份有限公司 一种心脑血管和糖尿病相关四高指标复合质控品及其制备方法
IT202000015895A1 (it) * 2020-07-27 2022-01-27 Univ Cattolica Del Sacro Cuore L’impiego di acido arundico nella terapia della sclerosi multipla
JP2024519587A (ja) * 2021-05-26 2024-05-17 デウン ファーマシューティカル カンパニー リミテッド １－（５－（２，４－ジフルオロフェニル）－１－（（３－フルオロフェニル）スルホニル）－４－メトキシ－１ｈ－ピロール－３－イル）－ｎ－メチルメタンアミンの液状薬学的組成物を含む医薬品容器
CN113341019A (zh) * 2021-06-09 2021-09-03 江西省药品检验检测研究院 一种乳酸左氧氟沙星氯化钠注射液中依地酸盐的分析方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0632008T3 (da) * 1993-06-01 1998-09-23 Ono Pharmaceutical Co Pentansyrederivater
JPH0782146A (ja) * 1993-07-23 1995-03-28 Sagami Chem Res Center 抗痴呆薬
JPH07285911A (ja) * 1994-04-20 1995-10-31 New Japan Chem Co Ltd 脂肪族モノカルボン酸組成物
JPH0853351A (ja) * 1994-08-11 1996-02-27 Sagami Chem Res Center 酵素阻害剤、血管新生抑制剤、および癌転移抑制剤
JP3032447B2 (ja) 1995-04-24 2000-04-17 小野薬品工業株式会社 光学活性な２−プロピルオクタン酸の製造方法
JP3084345B2 (ja) * 1995-04-26 2000-09-04 小野薬品工業株式会社 光学活性な２−プロピルオクタン酸の製造方法
JPH10298072A (ja) 1997-04-17 1998-11-10 Panacea Biotec Ltd 非ステロイド性抗炎症剤の遷移金属錯体
US6043223A (en) * 1997-11-12 2000-03-28 The Regents Of The University Of California Enhanced opening of abnormal brain tissue capillaries
TWI268921B (en) 1999-02-18 2006-12-21 Ono Pharmaceutical Co A process for preparing (2R)-2-propyloctanoic acid
US6552082B2 (en) * 2000-06-29 2003-04-22 Ono Pharmaceutical Co., Ltd. Solution of N-[o-(p-pivaloyloxybenzenesulfonylamino)benzoyl] glycine monosodium salt tetra-hydrate and drug product thereof
JP4706950B2 (ja) 2000-07-18 2011-06-22 小野薬品工業株式会社 アストロサイト機能改善剤を有効成分として含有するパーキンソン病治療剤
KR100759771B1 (ko) * 2000-07-18 2007-10-04 오노 야꾸힝 고교 가부시키가이샤 성상세포 기능 개선제를 유효 성분으로 함유하는 파킨슨병치료제
CA2453478A1 (fr) * 2001-07-18 2003-01-30 Ono Pharmaceutical Co., Ltd. Agent pour le traitement des maladies ischemiques cerebrales

Also Published As

Publication number Publication date
NZ546231A (en) 2009-09-25
CN1889942A (zh) 2007-01-03
KR20060099525A (ko) 2006-09-19
US20070105956A1 (en) 2007-05-10
MXPA06003533A (es) 2006-06-08
RU2388467C2 (ru) 2010-05-10
EP1669065B1 (fr) 2012-07-18
JPWO2005032536A1 (ja) 2006-12-14
ZA200602690B (en) 2007-07-25
CA2540670A1 (fr) 2005-04-14
EP1669065A4 (fr) 2009-12-16
EP1669065A1 (fr) 2006-06-14
RU2006114835A (ru) 2007-11-20
IS8430A (is) 2006-04-26
ES2390055T3 (es) 2012-11-06
ECSP066477A (es) 2007-03-29
IL174655A0 (en) 2006-08-20
CN1889942B (zh) 2010-12-15
US8053599B2 (en) 2011-11-08
SG146687A1 (en) 2008-10-30
BRPI0415001A (pt) 2006-11-07
TW200519080A (en) 2005-06-16
AU2004277826B2 (en) 2010-05-27
AU2004277826A1 (en) 2005-04-14
NO20061460L (no) 2006-07-03
WO2005032536A1 (fr) 2005-04-14
JP4715515B2 (ja) 2011-07-06
KR101144553B1 (ko) 2012-05-11

Similar Documents

Publication Publication Date Title
MA28142A1 (fr) Medicament contenant un acide (2r)-2-propyloctanoique comme principe actif
Clark et al. Possible central role of nitric oxide in conditions clinically similar to cerebral malaria
JP4933897B2 (ja) 眼内移行性促進水性点眼剤
US9433589B2 (en) Injectable pharmaceutical compositions comprising adrenaline and citric acid
MA34296B1 (fr) Composition retard injectable antipsychotique
JPH07116029B2 (ja) トラニラスト水溶液製剤
MA28143A1 (fr) Preparation de transfusion contenant un acide (2r)-2-propyloctanoique comme ingredient actif
JP6508655B2 (ja) メガリン拮抗剤
US20110118199A1 (en) Use of cns penetrating anticancer compounds for the treatment of protozoal diseases
AU718356B2 (en) A parenteral water-miscible non-intensely coloured injectable composition of non-steroidal anit-inflammatory drugs
JP5258329B2 (ja) プラノプロフェン含有水性医薬組成物
EP0599943A1 (fr) Complexe antagoniste de recepteur de leucotrienes-antihistamine
RU2666961C2 (ru) Эмульсионная композиция дифлюпредната, содержащая антимикробный металл
KR101153250B1 (ko) 글리시리진 고농도 제제
KR20190141871A (ko) 안정성을 개선한 이부프로펜 약학 조성물
US20140350097A1 (en) Treatment of hypotension associated with hemodialysis
JP4541504B2 (ja) トラニラストまたはその薬理学的に許容される塩を有効成分として含有する安定な水溶液製剤
FR2468366A1 (fr) Medicament antiglaucomateux a base d'acetazolamide ou de methazolamide
JP4508628B2 (ja) 眼科用組成物
FR2561522A1 (fr) Solution injectable, notamment pour le traitement de la cetose et son procede de preparation
KR930001302B1 (ko) 시플로플록사신의 주사용 조성물 및 그 제조방법
JP2004123632A (ja) 消炎鎮痛外用剤
CA2241502C (fr) Composition d'anti-inflammatoires non steroidiens, miscible a l'eau et faiblement coloree, a injecter par voie parenterale
JP6571391B2 (ja) 水性製剤
CH309033A (fr) Procédé de fabrication d'une préparation d'insuline injectable, avec effet retard.